These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31005213)

  • 1. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
    Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
    Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
    Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
    Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
    Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
    Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
    Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
    Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
    Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
    J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
    Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
    Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
    Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
    Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
    Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer.
    Mihai A; Milano MT; Santos A; Kennedy A; Thirion P; McDermott RS; Westrup J; Rock L; Armstrong J
    J Geriatr Oncol; 2019 May; 10(3):442-448. PubMed ID: 30420322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
    BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.
    Guillaume E; Tanguy R; Ayadi M; Claude L; Sotton S; Moncharmont C; Magné N; Martel-Lafay I
    Br J Radiol; 2022 Jan; 95(1129):20210533. PubMed ID: 34797724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
    Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor.
    Park S; Kim Y; Yoon WS; Rim CH
    Int J Radiat Biol; 2019 Sep; 95(9):1287-1294. PubMed ID: 31145016
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
    Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
    Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of conventional radiotherapy in small centrally located tumours or lymph nodes: minimal toxicity, remarkable survival but challenging loco-regional control.
    Knap MM; Khan S; Khalil AA; Møller DS; Hoffmann L
    Acta Oncol; 2023 Nov; 62(11):1433-1439. PubMed ID: 37707506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
    Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
    Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.